Price $74.31 |
Market Cap
3.08B
|
Sector Health Care |
Div. Growth
-
|
|
P/E
54.9
|
P/B
4.02
|
P/S
2.68
|
Dividend %
0.80%
|
|
P/CF
-
|
P/FCF
-
|
Op. Cash Flow
37.1K
|
FCF
-0.3
|
|
Op. Margin
-3.10%
|
Net Margin
7.60%
|
ROE
11.80%
|
ROI
-2.40%
|
|
ROA
3.80%
|
EPS Growth
176.20%
|
Current Ratio
2.0
|
Debt/Equity
132.10%
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Navidea Biopharmaceuticals Inc (NAVB) | $0.00 | - | - | 5M | Strong Buy |
| Chromadex Corp (CDXC) | $3.26 | - | - | 105.8M | Strong Buy |
| Cidara Therapeutics Inc (CDTX) | $11.55 | - | - | 78M | Strong Buy |
| InMed Pharmaceuticals Inc (INM) | $0.27 | - | - | 1.6M | Strong Buy |
| Rigel Pharmaceuticals Inc (RIGL) | $13.41 | - | - | 139.2M | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
